Innovent Biologics, Inc. (IVBXF) Stock Price & Analysis
Innovent Biologics, Inc. (IVBXF) — price $12.80 (+2.33%), as of the Oct 2, 2026 trading session; market cap $22.3B. Expected results Mar 31, 2027.
Educational signal · not a buy or sell recommendation · How to read this
Innovent Biologics, Inc. · IVBXF · Healthcare · Biotechnology
Innovent Biologics, Inc. is a biopharmaceutical firm headquartered in Suzhou, People's Republic of China, established in 2011.
Price as of Oct 2, 2026
Key Statistics
No publishable V2 score is available for this stock yet.
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $12.80 | |
| Change on the day | +2.33% | |
| 52-week range | $9.10 – $15.01 | |
| Market capitalisation | $22.3B | |
| Price / earnings (trailing) | 116.90 | |
| Shares traded on the day | 5.0K | |
| Beta (volatility vs the S&P 500) | 0.24 |
Price & events
Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file. Numbers key to the dated list. Point at or tab to any week for its close.
Events behind the price
- · Earnings results · below the recorded estimate
- · Earnings results · above the recorded estimate
Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.
Upcoming events
The provider's estimated date can change.
What to watch nextOther perspectives
Council score for Innovent Biologics (IVBXF): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Legends Council
4 lenses, 4 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Oct 5, 2026
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 9, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 9, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Oct 5, 2026, except a card that shows its own read date.
Watch the IVBXF film — every key number, told as a short cinematic story
~2 min · open the film
What is Innovent Biologics (IVBXF), and what does it report?
Short answer · as of
Innovent Biologics, Inc. is a biopharmaceutical firm headquartered in Suzhou, People's Republic of China, established in 2011. Innovent Biologics, Inc. (IVBXF) is classified as Healthcare / Biotechnology. SEC filing business address: 120 Broadway, 32ND Floor, NEW York, NY, 10271. It employs 7,502 people and is led by De-Chao Yu. In Q2 FY2026 it reported revenue of $1.27B and net income of $184M. The market values it at $22.3B.
What do the latest results show for Innovent Biologics (IVBXF)?
Short answer · as of
The most recent reported quarter, Q2 FY2026, carried revenue of $1.27B. Against analyst estimates the company has EPS beat 6 of 8 reports.
Did results meet expectations?
Reported earnings and revenue alongside the estimates recorded by the provider.
- Latest report · revenue
- $1.27B Aug 25, 2026
- Latest report · revenue estimate
- $1.31B Aug 25, 2026
- Latest report · revenue vs estimate
- Below estimate Aug 25, 2026
- Latest report · EPS vs estimate
- Above estimate Aug 25, 2026
| Report date | Revenue · reported | Revenue · estimate | EPS · reported | EPS · estimate |
|---|---|---|---|---|
| Aug 25, 2026 | $1.27B | $1.31B | $0.1030 | $0.0692 |
| Mar 26, 2026 | $1.01B | $985.90M | −$0.0014 | $0.0172 |
| Aug 27, 2025 | $830.16M | $790.35M | $0.0687 | $0.0251 |
| Mar 26, 2025 | $749.12M | $637.09M | $0.0250 | −$0.0315 |
Dates are report dates, not fiscal period ends. Revenue is in USD; EPS is USD per share, rounded to four decimals. The earnings feed does not establish a basic, diluted or adjusted basis. Earnings-feed EPS may differ from statement EPS; the two series are not combined.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q2 FY2026 | $1.27B | $184M | $0.10 (diluted) |
| Q4 FY2025 | $1.04B | -$3M | -$0.0037 (diluted) |
| Q2 FY2025 | $888M | $124M | $0.07 (diluted) |
| Q4 FY2024 | $816M | $44M | $0.03 (diluted) |
What are the financial strengths and risks for Innovent Biologics (IVBXF)?
Short answer
The distress and quality screens read Altman Z 5.34 · Piotroski F 8. Trailing ratios: ROE 4.8% · ROA 2.2% · current ratio 2.62 · earnings yield 0.7% · free-cash-flow yield 8.2%.
What should you watch next at Innovent Biologics (IVBXF)?
Short answer · as of
The next earnings report is expected on Mar 31, 2027.
What the records here don't tell us
- Detailed statement figures are not shown because their conversion to USD has not been verified.
- No insider Form 4 transaction falls inside the window this page reads.
Checked against the records this page reads, on the dates shown above.
What has been published about Innovent Biologics (IVBXF)?
What Investors Ask About Innovent Biologics (IVBXF) — Healthcare
These answers are editorial: 1 of these 8 answers is drawn from the IVBXF research dossier (written Jun 14, 2026 by gemini-2.5-flash); the other 7 are question templates that restate figures shown above. Figures in this section are not part of the source register.
Is IVBXF a good stock to buy?
Stock Expert AI does not rate IVBXF buy, sell or hold. Innovent Biologics, Inc. has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the IVBXF stock price today?
The last price recorded on this page for Innovent Biologics, Inc. (IVBXF) is $12.80, as of the Oct 2, 2026 trading session (source: Financial Modeling Prep (FMP) · quote). It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What are the main risks for IVBXF?
Innovent Biologics, Inc. faces several key risks inherent to the biopharmaceutical industry and its market position. A primary risk is the high failure rate associated with clinical trials; any setbacks or failures in its extensive pipeline could lead to significant financial losses and delays in bringing new therapies to market.
What are the key factors to evaluate for IVBXF?
Evaluate IVBXF on fundamentals, analyst consensus, and risk factors. P/E: 116.90x. For example, collaborations can facilitate co-development of novel therapies or provide pathways for international commercialization, expanding Innovent's reach beyond China. Not financial advice.
How frequently does IVBXF data refresh on this page?
IVBXF's price is the last quote we recorded, from the Oct 2, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven IVBXF's recent stock price performance?
Innovent Biologics, Inc. (IVBXF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Extensive and diversified pipeline of antibody drug candidates across multiple therapeutic areas. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider IVBXF overvalued or undervalued right now?
Innovent Biologics, Inc. (IVBXF) trades at 116.90x earnings. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research IVBXF before investing?
Before investing in Innovent Biologics, Inc. (IVBXF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Machine-generated analysis by Stock Expert AI — model gemini-2.5-flash, generated Jun 14, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources — records for every figure on this page (39 figures)
The 39 rows below are exactly the facts the evidence-backed sections of this page printed — the 10-second verdict, the MoonshotScore, price and market value, the five questions with their receipts, and the records behind this page. Known dates and sources are recorded on their own rows; an em dash or UNRECORDED tier preserves a stored observation without inventing either. The quarterly income statement is provider-standardized (FMP) under one row, and scale definitions — a 0-100 rating, the band ladder, the Piotroski 0–9 range — are fixed rather than measured. No number in those sections was generated by a model. The register does not cover quoted third-party headlines, the dated council readings, or the Frequently Asked Questions; each of those says where it came from where it stands.
"As of" is the date the value is true for where the source carries one — a quarter end, a filing date, a price close, the day the score was computed. A cached observation with no source date remains undated; the page publication date is not used as a substitute.
OFFICIAL — 1 fact from SEC filings and earnings calls
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
id.hq | SEC filing business address | 120 Broadway, 32ND Floor, NEW York, NY, 10271 | OFFICIAL | SEC EDGAR filer business address — The SEC filer business address. Our market-data provider separately lists "168 Dongping Street, Suzhou, JS, 215123, CN". The FMP company description names Suzhou as the headquarters; this page uses the address in this row. |
FMP — 31 facts from Financial Modeling Prep endpoint families
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
px.last | Latest provided price | $12.80 | FMP | Financial Modeling Prep (FMP) · quote — Dated to the US trading session the price belongs to, derived from the quote record's timestamp (weekend and pre-open reads roll back to the previous weekday; exchange holidays are not modelled). The record does not establish an exchange execution time. Retrieved 2026-10-04T20:54:46.687Z. | |
px.change | Change on the day | +2.33% | FMP | Financial Modeling Prep (FMP) · quote | |
px.mcap | Market capitalisation | $22.3B | FMP | Financial Modeling Prep (FMP) · quote — Date unknown Market cap record date: 2026-10-02. FMP quote timestamp: 2026-10-02T20:00:00.000Z. Captured from FMP at 2026-10-04T20:54:45.644Z. No share-count basis is inferred; this page preserves the reported amount instead of recalculating it from shares. | |
earn.next | Next earnings date | Mar 31, 2027 | FMP | Financial Modeling Prep (FMP) earnings calendar — The date is our provider's estimate until the company confirms it. | |
id.business_summary | Business description (FMP excerpt) | Innovent Biologics, Inc. is a biopharmaceutical firm headquartered in Suzhou, People's Republic of China, established in 2011. | FMP | Financial Modeling Prep (FMP) company profile — Deterministic excerpt derived from id.description; source and date describe the input fact, not a new provider observation | |
px.change_abs | Change on the day, in dollars | +$0.292 | FMP | Financial Modeling Prep (FMP) · quote | |
px.pe | Price / earnings (trailing) | 116.90 | FMP | Financial Modeling Prep (FMP) · quote | |
px.volume | Shares traded on the day | 5.0K | FMP | Financial Modeling Prep (FMP) · quote | |
px.beta | Beta | 0.24 | FMP | Financial Modeling Prep (FMP) company profile | |
id.sector | Sector / industry (provider taxonomy) | Healthcare / Biotechnology | FMP | Financial Modeling Prep (FMP) company profile | |
id.employees | Employees | 7,502 | FMP | Financial Modeling Prep (FMP) company profile | |
id.ceo | Chief executive | De-Chao Yu | FMP | Financial Modeling Prep (FMP) key executives (proxy-derived) — Titles and pay come from the company's proxy statement as our provider parsed it. | |
fin.q_revenue | Revenue, Q2 FY2026 | $1.27B | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
fin.q_income | Net income, Q2 FY2026 | $184M | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
earn.history.depth.2026-08-25.revenue_actual | Revenue · reported — report date 2026-08-25 | $1.27B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-08-25.revenue_estimated | Revenue · estimate — report date 2026-08-25 | $1.31B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-08-25.eps_actual | EPS · reported — report date 2026-08-25 | $0.1030 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-08-25.eps_estimated | EPS · estimate — report date 2026-08-25 | $0.0692 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-03-26.revenue_actual | Revenue · reported — report date 2026-03-26 | $1.01B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-03-26.revenue_estimated | Revenue · estimate — report date 2026-03-26 | $985.90M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-03-26.eps_actual | EPS · reported — report date 2026-03-26 | −$0.0014 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-03-26.eps_estimated | EPS · estimate — report date 2026-03-26 | $0.0172 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-08-27.revenue_actual | Revenue · reported — report date 2025-08-27 | $830.16M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-08-27.revenue_estimated | Revenue · estimate — report date 2025-08-27 | $790.35M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-08-27.eps_actual | EPS · reported — report date 2025-08-27 | $0.0687 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-08-27.eps_estimated | EPS · estimate — report date 2025-08-27 | $0.0251 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-03-26.revenue_actual | Revenue · reported — report date 2025-03-26 | $749.12M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-03-26.revenue_estimated | Revenue · estimate — report date 2025-03-26 | $637.09M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-03-26.eps_actual | EPS · reported — report date 2025-03-26 | $0.0250 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-03-26.eps_estimated | EPS · estimate — report date 2025-03-26 | −$0.0315 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
fin.q_table | Quarterly income statement | 4 quarters through Q2 FY2026 | FMP | Financial Modeling Prep (FMP) · income statement (quarterly), as filed |
UNRECORDED — 4 facts from stored observations whose source was not recorded
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
px.range52 | 52-week range | $9.10 – $15.01 | UNRECORDED | Stored company-profile observation — Captured 2026-10-02 | |
earn.history | Reported versus estimated, recent quarters | EPS beat 6 of 8 | UNRECORDED | Stored earnings-history observation — Captured 2026-10-02 · Expired observation | |
fin.scores | Distress and quality screens | Altman Z 5.34 · Piotroski F 8 | UNRECORDED | Stored financial-scores observation — Captured 2026-10-04 · Expired observation | |
fin.ratios | Return and yield ratios (trailing twelve months) | ROE 4.8% · ROA 2.2% · current ratio 2.62 · earnings yield 0.7% · free-cash-flow yield 8.2% | — | UNRECORDED | Stored key metrics — Date unknown |
COMPUTED — 2 facts from our arithmetic, formula restated
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
earn.history.depth.2026-08-25.revenue_actual.comparison | Latest report · revenue vs estimate | Below estimate | Report date · | COMPUTED | Computed from Financial Modeling Prep (FMP) earnings — Earnings-history note — Method: compare reported revenue ($1.27B) with the recorded estimate ($1.31B) at displayed precision. Equal displayed values are in line. This compares reported results with recorded estimates, not investment returns. |
earn.history.depth.2026-08-25.eps_actual.comparison | Latest report · EPS vs estimate | Above estimate | Report date · | COMPUTED | Computed from Financial Modeling Prep (FMP) earnings — Earnings-history note — Method: compare reported EPS ($0.1030) with the recorded estimate ($0.0692) at displayed precision. Equal displayed values are in line. This compares reported results with recorded estimates, not investment returns. |
OURS — 1 fact from Stock Expert AI's own score and rank
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
gap.statement_currency | Statement currency limitation | Detailed statement figures are not shown because their conversion to USD has not been verified. | OURS | Stock Expert AI currency-basis check |
Fact-family notes
- Earnings-history note. Source series as of 2026-08-25. Dates are report dates, not fiscal period ends. Revenue is in USD; EPS is USD per share, rounded to four decimals. The earnings feed does not establish a basic, diluted or adjusted basis. Earnings-feed EPS may differ from statement EPS; the two series are not combined. Applies to Fact IDs:
earn.history.depth.2026-08-25.revenue_actual,earn.history.depth.2026-08-25.revenue_estimated,earn.history.depth.2026-08-25.revenue_actual.comparison,earn.history.depth.2026-08-25.eps_actual.comparison,earn.history.depth.2026-08-25.eps_actual,earn.history.depth.2026-08-25.eps_estimated,earn.history.depth.2026-03-26.revenue_actual,earn.history.depth.2026-03-26.revenue_estimated,earn.history.depth.2026-03-26.eps_actual,earn.history.depth.2026-03-26.eps_estimated,earn.history.depth.2025-08-27.revenue_actual,earn.history.depth.2025-08-27.revenue_estimated,earn.history.depth.2025-08-27.eps_actual,earn.history.depth.2025-08-27.eps_estimated,earn.history.depth.2025-03-26.revenue_actual,earn.history.depth.2025-03-26.revenue_estimated,earn.history.depth.2025-03-26.eps_actual,earn.history.depth.2025-03-26.eps_estimated.
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Data provided for informational purposes only.